Analyst Price Targets — RDY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 25, 2026 7:31 pm | — | Jefferies | $13.90 | $13.21 | TheFly | Dr. Reddy's upgraded to Hold from Underperform at Jefferies |
| October 12, 2026 10:06 am | Tausif Shaikh | BNP Paribas | $14.80 | $12.48 | TheFly | Dr. Reddy's upgraded to Outperform from Neutral at BNP Paribas |
Latest News for RDY
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.
Dr. Reddy's Laboratories Ltd (NYSE: RDY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.92 and traded as high as $12.94. Dr. Reddy's Laboratories shares last traded at $12.7650, with a volume of 3,738,869 shares traded. Wall Street Analyst Weigh
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RDY.
U.S. House Trading
No House trades found for RDY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.